Bottom line
IDNA vs FTXH: the short answer
IDNA (iShares Genomics Immunology and Healthcare ETF) and FTXH (First Trust Nasdaq Pharmaceuticals ETF) are quite different portfolios: only about 17% of their top holdings (by weight) are shared.
IDNA is cheaper at 0.47% vs 0.6% — a difference of $13 a year per $10,000 invested.
Over five years, FTXH returned +6.5% a year vs −4.8% for IDNA (reporting dates differ).
Updated Nov 19, 2026
IDNA vs FTXH side by side
| IDNA | FTXH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | iShares | First Trust |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.47% | 0.6% |
| Annual cost per $10k | $47 | $60 |
| 10-yr cost on $10k (prospectus) | $591 | — |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | −1.0% | +24.0% |
| 5-yr return (annualized) | −4.8% | +6.5% |
| 10-yr return (annualized) | — | — |
| Best quarter | +41.9% | +18.3% |
| Worst quarter | −21.5% | −17.4% |
| Net assets (fund) | $190.9M | $36.2M |
| Number of holdings | 61 | 51 |
| Portfolio turnover | 49% | 35% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IDNA | FTXH | Difference |
|---|---|---|---|
| 2024 | −1.0% | +3.0% | −4.0% |
| 2023 | −7.8% | −1.4% | −6.4% |
| 2022 | −42.1% | +2.5% | −44.6% |
| 2021 | −4.0% | +6.1% | −10.1% |
| 2020 | +54.5% | +10.9% | +43.6% |
Source: Fund prospectus bar charts
Holdings overlap
5 of IDNA's top 25 holdings also appear in FTXH's top 25.
| Holding | IDNA | FTXH |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4.35% | 2.72% |
| Incyte Corporation | 4.23% | 2.39% |
| Merck & Co., Inc. | 3.91% | 7.07% |
| Vertex Pharmaceuticals Incorporated | 3.87% | 3.41% |
| Exelixis, Inc. | 3.65% | 1.72% |
Source: SEC Form N-PORT
IDNA top 10
- BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares — 10.39%
- Bayer Aktiengesellschaft — 4.81%
- Twist Bioscience Corp — 4.79%
- Revolution Medicines, Inc. — 4.55%
- Regeneron Pharmaceuticals, Inc. — 4.35%
- Genmab A/s — 4.23%
- Incyte Corporation — 4.23%
- Moderna, Inc. — 4.19%
- Takeda Pharmaceutical Company Limited — 4.05%
- Merck & Co., Inc. — 3.91%
FTXH top 10
- Eli Lilly & Company — 7.77%
- Abbvie Inc — 7.39%
- Merck & Company Inc — 7.07%
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- Cardinal Health Inc — 3.53%
- Vertex Pharmaceuticals Inc — 3.41%
- Amgen Inc — 3.18%
FAQ
What is the difference between IDNA and FTXH?
Which is cheaper, IDNA or FTXH?
Should I own both IDNA and FTXH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.